Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher B Granger

Showing results (371-380 of 910) with videos related to

Pageof 91
Sort By:
The American Journal of Cardiology|January 6, 2009
Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)Manesh R Patel, Matthias E Pfisterer, Amadeo Betriu, et al.
European Heart Journal|July 10, 2009
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysisPeter R Sinnaeve, Justin A Ezekowitz, Kris Bogaerts, et al.
Heart (British Cardiac Society)|February 4, 2016
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillationZiad Hijazi, Julia Aulin, Ulrika Andersson, et al.
Journal of the American College of Cardiology|March 14, 2020
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE TrialMichel Zeitouni, Anna Giczewska, Renato D Lopes, et al.
Circulation|July 6, 2006
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graftRajendra H Mehta, Emily Honeycutt, Eric D Peterson, et al.
The American Journal of Cardiology|January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)John K French, Anne S Hellkamp, Paul W Armstrong, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Heart Journal|September 1, 2011
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromePh Gabriel Steg, Shamir R Mehta, J Wouter Jukema, et al.
Stroke|November 2, 2017
Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or WarfarinDragos Vinereanu, Renato D Lopes, Hillary Mulder, et al.
Archives of Internal Medicine|February 25, 2009
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary EventsPeter R Sinnaeve, P Gabriel Steg, Keith A A Fox, et al.
Pageof 91

Showing results (371-380 of 910) with videos related to

Sort By:
Pageof 91
The American Journal of Cardiology|January 6, 2009
Comparison of six-month outcomes for primary percutaneous revascularization for acute myocardial infarction with drug-eluting versus bare metal stents (from the APEX-AMI study)Manesh R Patel, Matthias E Pfisterer, Amadeo Betriu, et al.
European Heart Journal|July 10, 2009
Reperfusion before percutaneous coronary intervention in ST-elevation myocardial infarction patients is associated with lower N-terminal pro-brain natriuretic peptide levels during follow-up, irrespective of pre-treatment with full-dose fibrinolysisPeter R Sinnaeve, Justin A Ezekowitz, Kris Bogaerts, et al.
Heart (British Cardiac Society)|February 4, 2016
Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillationZiad Hijazi, Julia Aulin, Ulrika Andersson, et al.
Journal of the American College of Cardiology|March 14, 2020
Clinical and Pharmacological Effects of Apixaban Dose Adjustment in the ARISTOTLE TrialMichel Zeitouni, Anna Giczewska, Renato D Lopes, et al.
Circulation|July 6, 2006
Impact of internal mammary artery conduit on long-term outcomes after percutaneous intervention of saphenous vein graftRajendra H Mehta, Emily Honeycutt, Eric D Peterson, et al.
The American Journal of Cardiology|January 28, 2010
Mechanical complications after percutaneous coronary intervention in ST-elevation myocardial infarction (from APEX-AMI)John K French, Anne S Hellkamp, Paul W Armstrong, et al.
American Heart Journal|November 19, 2011
Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programCono A Ariti, John G F Cleland, Stuart J Pocock, et al.
European Heart Journal|September 1, 2011
RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndromePh Gabriel Steg, Shamir R Mehta, J Wouter Jukema, et al.
Stroke|November 2, 2017
Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or WarfarinDragos Vinereanu, Renato D Lopes, Hillary Mulder, et al.
Archives of Internal Medicine|February 25, 2009
Association of elevated fasting glucose with increased short-term and 6-month mortality in ST-segment elevation and non-ST-segment elevation acute coronary syndromes: the Global Registry of Acute Coronary EventsPeter R Sinnaeve, P Gabriel Steg, Keith A A Fox, et al.
Pageof 91